Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
Trial ID or NCT#
The purpose of the study is to first determine if temozolomide plus vorinostat in combination can control relapsed or refractory acute myeloid leukemia (AML) and determine if this combination can be safely taken. The study will look at the side effects of the Temozolomide plus Vorinostat in combination and whether the treatment schedule is tolerated.
Temozolomide Plus Vorinostat in Patients With Relapse/Refractory Acute Myeloid Leukemia (AML)
Contact us to find out if this trial is right for you.